BiomarkerDriven NSCLC Paradigm Advances With Novel Agents Liquid Biopsies

Biomarker-Driven NSCLC Paradigm Advances With Novel Agents, Liquid Biopsies

Jonathan W. Goldman, MD, discusses the current landscape of biomarker-driven lung cancer.

More From BioPortfolio on "Biomarker-Driven NSCLC Paradigm Advances With Novel Agents, Liquid Biopsies"